The Efficacy, Safety, and Long-Term Prognosis of Low-Dose Selumetinib in the Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas in Chinese Children: a Multicenter Randomized Controlled Trial
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
- Acronyms LS-NF1PNs
- 13 Jan 2025 New trial record